SCHEMBL3460449

SCHEMBL3460449

Cc1ccccc1NC(=O)Nc1ccc(N)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 2/20 0.70
RAB9A P51151 8/20 0.66
NPC1 O15118 6/20 0.66
MAPT P10636 5/20 0.66
KMT2A Q03164 2/20 0.66
HTT P42858 2/20 0.66
MEN1 O00255 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.62
POLB P06746 2/20 0.58
KDR P35968 3/20 0.54
GHSR Q92847 1/20 0.54
KIT P10721 1/20 0.54
FLT3 P36888 1/20 0.54
IMPDH2 P12268 1/20 0.53
PDGFRB P09619 1/20 0.53
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
TP53 P04637 1/20 0.53
GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5852186 0.86 DDX3X (0.70) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL812756 0.86 DDX3X (0.80) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL3460448 0.84 RAB9A (0.71) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL16942599 0.84 RAB9A (0.62) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL1275926 0.84 RAB9A (0.75) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL17079606 0.83 RAB9A (0.66) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL687547 0.83 RAB9A (0.66) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL17084259 0.83 RAB9A (0.67) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL3460675 0.83 DDX3X (0.69) DDX3XRAB9ANPC1MAPTKMT2A
SCHEMBL5683215 0.83 DDX3X (0.65) DDX3XRAB9ANPC1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108794408-B Pyrimidine phenylurea anti-tumor compound and preparation method and application thereof 中国医科大学 2020-04-21 CN disclosed
EP-3432881-A1 USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS Azienda Ospedaliera Universitaria Senese (IT) 2019-01-30 EP disclosed
CN-109069484-A Purposes of the DDX3 inhibitor as antiproliferative 锡耶纳大学医院 2018-12-21 CN disclosed
CN-108794408-A Pyrimidine phenylurea anti-tumor compounds and its preparation method and application 中国医科大学 2018-11-13 CN disclosed
EP-3256461-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS Azienda Ospedaliera Universitaria Senese (IT) 2017-12-20 EP disclosed
WO-2017162834-A1 USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2017-09-28 WO disclosed
WO-2017162834-A1 USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2017-09-28 WO disclosed
CN-103717597-B Heterocyclic compounds as kinase inhibitors 原真股份有限公司 2017-07-04 CN disclosed
CN-103492389-B Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases 原真股份有限公司 2016-09-14 CN disclosed
WO-2016128541-A1 HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) 2016-08-18 WO disclosed
EP-1406865-A2 SUCCINIC ACID DERIVATIVES Bayer HealthCare AG (DE) 2004-04-14 EP disclosed
US-20040058904-A1 Beta-amino acid derivatives as integrin receptor antagonists BAYER AKTIENGESELLSCHAFT (DE) 2004-03-25 US disclosed
EP-1326828-A1 BETA-AMINO ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS Bayer Aktiengesellschaft (DE) 2003-07-16 EP disclosed
WO-2003004460-A2 SUCCINIC ACID DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-01-16 WO disclosed
WO-2003004460-A2 SUCCINIC ACID DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-01-16 WO disclosed
WO-2002030874-A2 ALIPHATIC, CYCLIC AMINO CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2002-04-18 WO disclosed
WO-2002030875-A1 BETA-AMINO ACID DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2002-04-18 WO disclosed
WO-2002030876-A2 CYCLIC CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2002-04-18 WO disclosed
EP-1173415-A1 DIPHENYLUREA DERIVATIVES AstraZeneca AB (SE) 2002-01-23 EP disclosed
WO-2000064866-A1 DIPHENYLUREA DERIVATIVES ASTRAZENECA AB (SE) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058904-A1 Beta-amino acid derivatives as integrin receptor antagonists ITGAL, ITGB1, ITGB2 DDX3X 4861/4885RAB9A 1080/4885NPC1 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.